Graves Ophthalmopathy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited

Posted on
by

Graves Ophthalmopathy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited
The Graves Ophthalmopathy Market Forecast report offers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the 7MM.

The Graves Ophthalmopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Ophthalmopathy pipeline products will significantly revolutionize the Graves Ophthalmopathy market dynamics.  

 

DelveInsight’s “Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Graves Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Graves Ophthalmopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Ophthalmopathy Market Insights

 

Some of the key facts of the Graves Ophthalmopathy Market Report: 

  • The Graves Ophthalmopathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In 2022, approximately 2,385,900 cases of Graves Ophthalmopathy were reported in the seven major markets (7MM), and it is anticipated that these figures will rise throughout the study period from 2019 to 2032.

  • In 2022, it was estimated that there were approximately 448,800 diagnosed prevalent cases of Graves Ophthalmopathy in the United States. It is projected that these cases will increase over the study period from 2019 to 2032.

  • In 2022, Germany had the highest number of diagnosed prevalent cases of Graves Ophthalmopathy patients among the EU4 and the UK, with around 105,900 cases. Conversely, Spain had the fewest cases, with approximately 59,200 cases in 2022.

  • In the United States, the number of diagnosed prevalent cases of Graves Ophthalmopathy was higher among females compared to males in 2022, with approximately 89,800 cases in males and around 359,000 cases in females.

  • Key Graves Ophthalmopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others

  • Key Graves Ophthalmopathy Therapies: RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, Batoclimab, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others

  • The Graves Ophthalmopathy epidemiology based on gender analyzed that the females are affected more as compared to males in the case of Graves Ophthalmopathy

 

Graves Ophthalmopathy Overview

Graves Ophthalmopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is a condition primarily associated with an autoimmune disorder called Graves’ disease. Graves’ disease is characterized by an overactive thyroid gland (hyperthyroidism), and Graves Ophthalmopathy is one of its potential complications.

 

Get a Free sample for the Graves Ophthalmopathy Market Report – 

https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

 

Graves Ophthalmopathy Market  

The dynamics of the Graves Ophthalmopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated.”

 

Graves Ophthalmopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Download the report to understand which factors are driving Graves Ophthalmopathy epidemiology trends @ Graves Ophthalmopathy Epidemiological Insights

 

Graves Ophthalmopathy Epidemiology Segmentation:

The Graves Ophthalmopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Graves Ophthalmopathy

  • Prevalent Cases of Graves Ophthalmopathy by severity

  • Gender-specific Prevalence of Graves Ophthalmopathy

  • Diagnosed Cases of Episodic and Chronic Graves Ophthalmopathy

 

Graves Ophthalmopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Ophthalmopathy market or expected to get launched during the study period. The analysis covers Graves Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graves Ophthalmopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Graves Ophthalmopathy treatment, visit @ Graves Ophthalmopathy Medications

 

Graves Ophthalmopathy Therapies and Key Companies

  • RVT-1401: Immunovant Sciences GmbH

  • Teprotumumab: Horizon Pharma USA, Inc.

  • VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.

  • Batoclimab: Immunovant Sciences GmbH

  • TOUR006 – 20 MG: Tourmaline Bio, Inc.

  • IBI311: Innovent Biologics (Suzhou) Co. Ltd.

  • lonigutamab: ACELYRIN Inc.

  • Satralizumab: Hoffmann-La Roche

  • TEPEZZA: Horizon Therapeutics USA, Inc.

  • LASN01: Lassen Therapeutics Inc.

  • CFZ533: Novartis

  • linsitinib: Sling Therapeutics, Inc.

  • LASN01: Lassen Therapeutics

 

Graves Ophthalmopathy Market Strengths

  • The recent US FDA approval of Horizon’s TEPEZZA has accelerated the research and development of GO.

  • Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.

 

Graves Ophthalmopathy Market opportunities

  • Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.

  • Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.

 

Scope of the Graves Ophthalmopathy Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Graves Ophthalmopathy Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others

  • Key Graves Ophthalmopathy Therapies: RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, Batoclimab, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others

  • Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy current marketed and Graves Ophthalmopathy emerging therapies

  • Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy market drivers and Graves Ophthalmopathy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Graves Ophthalmopathy Unmet Needs, KOL’s views, Analyst’s views, Graves Ophthalmopathy Market Access and Reimbursement 

 

Discover more about therapies set to grab major Graves Ophthalmopathy market share @ Graves Ophthalmopathy market forecast

 

Table of Contents 

1. Graves Ophthalmopathy Market Report Introduction

2. Executive Summary for Graves Ophthalmopathy

3. SWOT analysis of Graves Ophthalmopathy

4. Graves Ophthalmopathy Patient Share (%) Overview at a Glance

5. Graves Ophthalmopathy Market Overview at a Glance

6. Graves Ophthalmopathy Disease Background and Overview

7. Graves Ophthalmopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves Ophthalmopathy 

9. Graves Ophthalmopathy Current Treatment and Medical Practices

10. Graves Ophthalmopathy Unmet Needs

11. Graves Ophthalmopathy Emerging Therapies

12. Graves Ophthalmopathy Market Outlook

13. Country-Wise Graves Ophthalmopathy Market Analysis (2019–2032)

14. Graves Ophthalmopathy Market Access and Reimbursement of Therapies

15. Graves Ophthalmopathy Market Drivers

16. Graves Ophthalmopathy Market Barriers

17.  Graves Ophthalmopathy Appendix

18. Graves Ophthalmopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/